Schonfeld Strategic Advisors’s NewAmsterdam Pharma NAMS Stock Holding History

Schonfeld Strategic Advisors’s Portfolio NAMS Stock Details NAMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-33,457	Closed	-$685K	–	2367
2025 Q1	$685K	Buy	33,457 +13,075	+64%	+$291K	﹤0.01%	1451
2024 Q4	$524K	Buy	+20,382	New	+$433K	﹤0.01%	1371
2024 Q3	–	Sell	-49,433	Closed	-$950K	–	2275
2024 Q2	$950K	Sell	49,433 -72,567	-59%	-$1.46M	0.01%	1231
2024 Q1	$2.89M	Buy	122,000 +55,100	+82%	+$1.12M	0.02%	857
2023 Q4	$747K	Buy	66,900 +2,200	+3%	+$20.2K	0.01%	1140
2023 Q3	$598K	Buy	64,700 +7,400	+13%	+$80.1K	﹤0.01%	1160
2023 Q2	$681K	Buy	57,300 +27,200	+90%	+$361K	0.01%	1109
2023 Q1	$399K	Buy	+30,100	New	+$380K	﹤0.01%	1261

Other funds holding NAMS

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Schonfeld Strategic Advisors's NAMS Position: Q2 2025 in Review

Schonfeld Strategic Advisors sold out of NewAmsterdam Pharma (NAMS) in Q2 2025, closing a stake of 33,457 shares — an estimated $685K sold.

Schonfeld Strategic Advisors first reported a position in NAMS in Q1 2023 and held it in 8 quarters. The position peaked at $2.89M in Q1 2024. 131 funds tracked by Wall St. Rank hold NAMS as of Q2 2025.

Schonfeld Strategic Advisors reported no remaining NewAmsterdam Pharma position as of Q2 2025 after selling out during the quarter.
Schonfeld Strategic Advisors sold 33,457 NewAmsterdam Pharma shares in Q2 2025, an estimated $685K.
Schonfeld Strategic Advisors first reported a position in NewAmsterdam Pharma in Q1 2023 and held it in 8 quarters.
Schonfeld Strategic Advisors's NewAmsterdam Pharma position peaked at $2.89M in Q1 2024.
131 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q2 2025.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.